However, by inhibiting negative regulation of inflammatory T cells, this treatment elicits toxicity which results in severe adverse events, including damage to organs such as the pituitary gland, where 10% of patients receiving CTLA-4 inhibitor (ipilimumab) develop hypophysitis. This evidence concerns the gene CTLA4 and hypophysitis.